Close Menu

CHICAGO — Cancer Genetics will later this year expand its menu of array-based tests to include assays for informing treatment of patients with diffuse large B-cell lymphoma and renal cell carcinoma.

Jane Houldsworth, the firm's vice president of R&D, said that CGI aims to obtain the appropriate licenses to offer the new tests as a service through its CLIA-compliant lab by the end of the year.

Houldsworth spoke with BioArray News during the Cancer Cytogenomics Microarray Consortium's annual meeting, held here this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A new analysis finds some cancers receive more nonprofit dollars than others.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.